Roth Affirms Keryx (KERX) at 'Buy'; ESRD Overhang Removed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
H.C. Wainwright Reiterates Buy on Keryx Biopharmaceuticals (KERX)
April 2, 2014 1:15 PM EDTH.C. Wainwright reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a price target of $21.00. Comments follow news the EMA plans to review Zerenex's MAA.
Analyst Reni Benjamin said, "Today, Keryx announced the European Medicines Agency (EMA) initiated a formal review of... More
Keryx Biopharma (KERX) Reports EMA Validation of Zerenex MAA
April 2, 2014 8:31 AM EDTKeryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that the European Medicines Agency ("EMA") has determined that the Company's Marketing Authorization Application ("MAA") seeking the approval of Zerenex (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis-dependent CKD, is valid. Validation of the MAA confirms that the submission is sufficiently... More
